[{"address1": "88 Sidney Street", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "617 649 8600", "website": "https://www.agios.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 383, "companyOfficers": [{"maxAge": 1, "name": "Mr. Brian M. Goff M.B.A.", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 1458975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cecilia  Jones", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 751482, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James William Burns", "age": 45, "title": "Corporate Secretary & Chief Legal Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 1019942, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sarah  Gheuens M.D., Ph.D.", "age": 43, "title": "Chief Medical Officer and Head of Research & Development", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 1247567, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tsveta  Milanova", "age": 46, "title": "Chief Commercial Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 939048, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lewis Clayton Cantley Ph.D.", "age": 74, "title": "Founder", "yearBorn": 1949, "fiscalYear": 2023, "totalPay": 50000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.", "age": 77, "title": "Founder", "yearBorn": 1946, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Craig B. Thompson M.D.", "age": 70, "title": "Founder", "yearBorn": 1953, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shin-San  Su Ph.D.", "age": 67, "title": "Founder", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. T. J. Washburn", "age": 41, "title": "VP, Controller & Principal Accounting Officer", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 3, "compensationRisk": 4, "shareHolderRightsRisk": 7, "overallRisk": 5, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 55.4, "open": 55.67, "dayLow": 52.75, "dayHigh": 55.67, "regularMarketPreviousClose": 55.4, "regularMarketOpen": 55.67, "regularMarketDayLow": 52.75, "regularMarketDayHigh": 55.67, "beta": 0.751, "trailingPE": 4.61235, "forwardPE": -9.764866, "volume": 908320, "regularMarketVolume": 908320, "averageVolume": 554831, "averageVolume10days": 991880, "averageDailyVolume10Day": 991880, "bid": 53.69, "ask": 53.91, "bidSize": 200, "askSize": 200, "marketCap": 3067084032, "fiftyTwoWeekLow": 20.96, "fiftyTwoWeekHigh": 62.58, "priceToSalesTrailing12Months": 93.30669, "fiftyDayAverage": 46.2348, "twoHundredDayAverage": 39.3473, "currency": "USD", "enterpriseValue": 2123160832, "profitMargins": 20.51377, "floatShares": 50506511, "sharesOutstanding": 57030200, "sharesShort": 4339238, "sharesShortPriorMonth": 3275023, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0761, "heldPercentInsiders": 0.01509, "heldPercentInstitutions": 1.0687001, "shortRatio": 9.39, "shortPercentOfFloat": 0.077199996, "impliedSharesOutstanding": 58748100, "bookValue": 28.527, "priceToBook": 1.8852315, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": 674307968, "trailingEps": 11.66, "forwardEps": -6.08, "enterpriseToRevenue": 64.591, "enterpriseToEbitda": -5.291, "52WeekChange": 1.5767441, "SandP52WeekChange": 0.29098952, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AGIO", "underlyingSymbol": "AGIO", "shortName": "Agios Pharmaceuticals, Inc.", "longName": "Agios Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1374672600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "52f076ec-0de6-382e-b01b-3ddfa165dcb4", "messageBoardId": "finmb_46539787", "gmtOffSetMilliseconds": -18000000, "currentPrice": 53.78, "targetHighPrice": 57.0, "targetLowPrice": 46.0, "targetMeanPrice": 53.875, "targetMedianPrice": 55.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 1004756992, "totalCashPerShare": 17.618, "ebitda": -401288000, "totalDebt": 60834000, "quickRatio": 8.438, "currentRatio": 8.993, "totalRevenue": 32871000, "debtToEquity": 3.74, "revenuePerShare": 0.582, "returnOnAssets": -0.18175, "returnOnEquity": 0.53655, "freeCashflow": -157062624, "operatingCashflow": -329161984, "revenueGrowth": 0.212, "operatingMargins": -11.46932, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-16"}]